| - GRCh37:
- Chr16:2098588-2115636
- GRCh38:
- Chr16:2048587-2065635
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Sep 27, 2016) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098597-2124416
- GRCh38:
- Chr16:2048596-2074415
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Jul 31, 2018) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098597-2098774
- GRCh38:
- Chr16:2048596-2048773
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Aug 12, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098611-2138617
- GRCh38:
- Chr16:2048610-2088616
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Nov 30, 2017) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098619
- GRCh38:
- Chr16:2048618
| TSC2 | M1I, M12I | not provided | Likely pathogenic (Sep 12, 2017) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098625-2098626
- GRCh38:
- Chr16:2048624-2048625
| TSC2 | T5fs, T16fs | not provided | Likely pathogenic (Jan 7, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098628
- GRCh38:
- Chr16:2048627
| TSC2 | T16fs, T5fs | Tuberous sclerosis 2 | Pathogenic (Apr 15, 2019) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098630-2098631
- GRCh38:
- Chr16:2048629-2048630
| TSC2 | S17fs, S6fs | Tuberous sclerosis 2 | Pathogenic (Feb 1, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098635-2098636
- GRCh38:
- Chr16:2048634-2048635
| TSC2 | K18fs, K7fs | Tuberous sclerosis 2 | Pathogenic (Dec 20, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098635
- GRCh38:
- Chr16:2048634
| TSC2 | D19fs, D8fs | not provided | Pathogenic (Oct 23, 2019) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098638
- GRCh38:
- Chr16:2048637
| TSC2 | D8fs, D19fs | Tuberous sclerosis 2 | Pathogenic (Jul 9, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098642
- GRCh38:
- Chr16:2048641
| TSC2 | S9*, S20* | Tuberous sclerosis 2 | Pathogenic (Aug 12, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098645-2131595
- GRCh38:
- Chr16:2048644-2081594
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Jun 30, 2016) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098647
- GRCh38:
- Chr16:2048646
| TSC2 | | not provided | Pathogenic (Oct 3, 2014) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098650
- GRCh38:
- Chr16:2048649
| TSC2 | K12*, K23* | Tuberous sclerosis 2 | Pathogenic (Jan 1, 1996) | no assertion criteria provided |
| - GRCh37:
- Chr16:2098656
- GRCh38:
- Chr16:2048655
| TSC2 | K14fs, K25fs | Tuberous sclerosis 2 | Pathogenic (Apr 9, 2019) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098658-2098659
- GRCh38:
- Chr16:2048657-2048658
| TSC2 | K16*, K27* | Tuberous sclerosis 2 | Pathogenic (Oct 27, 2022) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2098659-2098665
- GRCh38:
- Chr16:2048658-2048664
| TSC2 | K27fs, K16fs | Tuberous sclerosis 2 | Pathogenic (Jul 10, 2020) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098700-2098718
- GRCh38:
- Chr16:2048699-2048717
| TSC2 | S30fs, S41fs | not provided | Pathogenic (Sep 18, 2018) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098708-2098718
- GRCh38:
- Chr16:2048707-2048717
| TSC2 | E32fs, E43fs | Tuberous sclerosis 2 | Pathogenic (Aug 9, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098720-2098721
- GRCh38:
- Chr16:2048719-2048720
| TSC2 | Q35fs, Q46fs | Tuberous sclerosis 2 | Pathogenic (Mar 26, 2019) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098721-2098722
- GRCh38:
- Chr16:2048720-2048721
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Aug 12, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098725
- GRCh38:
- Chr16:2048724
| TSC2 | E37*, E48* | Tuberous sclerosis 2 | Likely pathogenic (Jan 4, 2023) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098727-2098728
- GRCh38:
- Chr16:2048726-2048727
| TSC2 | I39fs, I50fs | not provided | Pathogenic (Sep 15, 2017) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098730-2098731
- GRCh38:
- Chr16:2048729-2048730
| TSC2 | I39fs, I50fs | Tuberous sclerosis 2 | Pathogenic (Jan 13, 2019) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098731-2098732
- GRCh38:
- Chr16:2048730-2048731
| TSC2 | A53fs, A42fs | Tuberous sclerosis 2 | Pathogenic (Sep 13, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098736
- GRCh38:
- Chr16:2048735
| TSC2 | T41fs, T52fs | Tuberous sclerosis 2 | Pathogenic (Jan 3, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098746-2098747
- GRCh38:
- Chr16:2048745-2048746
| TSC2 | I44fs, I55fs | not provided | Pathogenic (Jul 16, 2015) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098747-2098748
- GRCh38:
- Chr16:2048746-2048747
| TSC2 | L45fs, L56fs | not provided | Pathogenic (Mar 1, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098748-2098751
- GRCh38:
- Chr16:2048747-2048750
| TSC2 | L45fs, L56fs | Tuberous sclerosis 2, not provided | Pathogenic (Nov 7, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2098750-2098755
- GRCh38:
- Chr16:2048749-2048754
| TSC2 | | not provided | Pathogenic (Nov 22, 2016) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098751-2098754
- GRCh38:
- Chr16:2048750-2048753
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Aug 12, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098751-2098752
- GRCh38:
- Chr16:2048750-2048751
| TSC2 | | not provided, Tuberous sclerosis 2 | Pathogenic (Nov 7, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2098752
- GRCh38:
- Chr16:2048751
| TSC2 | R46*, R57* | Tuberous sclerosis 2 | Pathogenic (Apr 9, 2020) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098756
- GRCh38:
- Chr16:2048755
| TSC2 | | not provided, Tuberous sclerosis 2 | Pathogenic (Aug 12, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2098759
- GRCh38:
- Chr16:2048758
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Sep 1, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2098759
- GRCh38:
- Chr16:2048758
| TSC2 | | Lymphangiomyomatosis, Isolated focal cortical dysplasia type II, Tuberous sclerosis 2, not provided, Tuberous sclerosis 2 | Pathogenic/Likely pathogenic (Feb 28, 2022) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2100381-2115656
- GRCh38:
- Chr16:2050380-2065655
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (May 25, 2018) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2100391-2100497
- GRCh38:
- Chr16:2050390-2050496
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Oct 29, 2018) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2100399
- GRCh38:
- Chr16:2050398
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Jun 22, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2100400
- GRCh38:
- Chr16:2050399
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Nov 7, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2100401
- GRCh38:
- Chr16:2050400
| TSC2 | E47*, E58* | not provided | Pathogenic (Feb 20, 2017) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2100422-2100423
- GRCh38:
- Chr16:2050421-2050422
| TSC2 | L5fs, L65fs, L54fs | Hereditary cancer-predisposing syndrome | Pathogenic (Sep 3, 2020) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2100466
- GRCh38:
- Chr16:2050465
| TSC2 | T21fs, T70fs, T81fs | Tuberous sclerosis 2 | Pathogenic (Jun 28, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2100482
- GRCh38:
- Chr16:2050481
| TSC2 | E85*, E74*, E25* | Hereditary cancer-predisposing syndrome | Pathogenic (Jan 26, 2017) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2100488
- GRCh38:
- Chr16:2050487
| TSC2 | | Isolated focal cortical dysplasia type II, Lymphangiomyomatosis, Tuberous sclerosis 2, Tuberous sclerosis 2 | Pathogenic/Likely pathogenic (Feb 23, 2023) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2103323-2107460
- GRCh38:
- Chr16:2053322-2057459
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Aug 4, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103341
- GRCh38:
- Chr16:2053340
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Sep 3, 2013) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103342
- GRCh38:
- Chr16:2053341
| TSC2 | | Tuberous sclerosis 2 | Likely pathogenic (Oct 4, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103343-2103345
- GRCh38:
- Chr16:2053342-2053344
| TSC2 | H76*, H87*, H27* | Hereditary cancer-predisposing syndrome | Pathogenic (Sep 14, 2020) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103343-2110814
- GRCh38:
- Chr16:2053342-2060813
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Apr 7, 2016) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103362
- GRCh38:
- Chr16:2053361
| TSC2 | W82*, W33*, W93* | Tuberous sclerosis 2 | Pathogenic (Apr 12, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103363
- GRCh38:
- Chr16:2053362
| TSC2 | W82*, W33*, W93* | Tuberous sclerosis 2 | Pathogenic (Aug 31, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103364
- GRCh38:
- Chr16:2053363
| TSC2 | K83fs, K94fs, K34fs | Tuberous sclerosis 2 | Pathogenic (Jul 6, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103367-2103419
- GRCh38:
- Chr16:2053366-2053418
| TSC2 | V96fs, V36fs, V85fs | Tuberous sclerosis 2 | Pathogenic (Aug 27, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103384-2103385
- GRCh38:
- Chr16:2053383-2053384
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Oct 1, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103385
- GRCh38:
- Chr16:2053384
| TSC2 | Q90*, Q41*, Q101* | not provided, Tuberous sclerosis 2, Hereditary cancer-predisposing syndrome
| Pathogenic (Jul 17, 2022) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2103409-2103410
- GRCh38:
- Chr16:2053408-2053409
| TSC2 | H110fs, H50fs, H99fs | Tuberous sclerosis 2 | Pathogenic (Feb 12, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103428
- GRCh38:
- Chr16:2053427
| TSC2 | L104P, L115P, L55P | Tuberous sclerosis 2 | Likely pathogenic (Aug 28, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103438-2103439
- GRCh38:
- Chr16:2053437-2053438
| TSC2 | I59fs, I119fs, I108fs | Tuberous sclerosis 2 | Pathogenic (Aug 31, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103445
- GRCh38:
- Chr16:2053444
| TSC2 | Q110*, Q121*, Q61* | Hereditary cancer-predisposing syndrome, not provided | Pathogenic (Feb 1, 2022) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2103446
- GRCh38:
- Chr16:2053445
| TSC2 | Q110fs, Q61fs, Q121fs | not provided | Pathogenic (Jun 4, 2018) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103448-2103463
- GRCh38:
- Chr16:2053447-2053462
| TSC2 | | Tuberous sclerosis 2 | Likely pathogenic (Oct 22, 2018) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103454
- GRCh38:
- Chr16:2053453
| TSC2 | V64L, V113L | Tuberous sclerosis 2 | Pathogenic/Likely pathogenic (Oct 5, 2022) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2103454
- GRCh38:
- Chr16:2053453
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Aug 27, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103454
- GRCh38:
- Chr16:2053453
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Dec 2, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2103458
- GRCh38:
- Chr16:2053457
| TSC2 | | Tuberous sclerosis 2, not provided | Pathogenic/Likely pathogenic (Nov 7, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2104295
- GRCh38:
- Chr16:2054294
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Mar 18, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104296
- GRCh38:
- Chr16:2054295
| TSC2 | | Tuberous sclerosis 2, not provided | Pathogenic (Nov 7, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2104296
- GRCh38:
- Chr16:2054295
| TSC2 | | Hereditary cancer-predisposing syndrome | Pathogenic (May 21, 2018) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104300
- GRCh38:
- Chr16:2054299
| TSC2 | E114*, E65*, E125*, E77* | Tuberous sclerosis 2 | Pathogenic (Apr 17, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104305
- GRCh38:
- Chr16:2054304
| TSC2 | L67fs, L116fs, L127fs, L79fs | Tuberous sclerosis 2 | Pathogenic (Dec 29, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104307-2104308
- GRCh38:
- Chr16:2054306-2054307
| TSC2 | V81fs, V69fs, V129fs, V118fs | Hereditary cancer-predisposing syndrome, Tuberous sclerosis 2, not provided
| Pathogenic (Nov 28, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2104308
- GRCh38:
- Chr16:2054307
| TSC2 | V129fs, V81fs, V118fs, V69fs | Tuberous sclerosis 2 | Pathogenic (Oct 7, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104317-2104318
- GRCh38:
- Chr16:2054316-2054317
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Sep 19, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104318
- GRCh38:
- Chr16:2054317
| TSC2 | R120*, R131*, R71*, R83* | Tuberous sclerosis 2, not provided | Pathogenic (Nov 7, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2104318-2104319
- GRCh38:
- Chr16:2054317-2054318
| TSC2 | R131fs, R120fs, R71fs, R83fs | Hereditary cancer-predisposing syndrome | Pathogenic (Mar 23, 2015) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104322
- GRCh38:
- Chr16:2054321
| TSC2 | L122fs, L133fs, L73fs, L85fs | Tuberous sclerosis 2 | Pathogenic (Jun 11, 2020) | no assertion criteria provided |
| - GRCh37:
- Chr16:2104360
- GRCh38:
- Chr16:2054359
| TSC2 | E145*, E85*, E134*, E97* | Tuberous sclerosis 2 | Pathogenic (May 28, 2019) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104372
- GRCh38:
- Chr16:2054371
| TSC2 | E138*, E149*, E89*, E101* | not provided | Pathogenic (Aug 10, 2017) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104381
- GRCh38:
- Chr16:2054380
| TSC2 | E141*, E92*, E104*, E152* | Tuberous sclerosis 2 | Pathogenic (Jun 27, 2016) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104385
- GRCh38:
- Chr16:2054384
| TSC2 | F154fs, F143fs, F94fs, F106fs | not provided | Pathogenic (Nov 25, 2016) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104398-2104399
- GRCh38:
- Chr16:2054397-2054398
| TSC2 | T110fs, T158fs, T147fs, T98fs | Tuberous sclerosis 2 | Pathogenic (Jun 7, 2019) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104400
- GRCh38:
- Chr16:2054399
| TSC2 | T147K, T158K, T98K, T110K | Tuberous sclerosis 2 | Likely pathogenic (Aug 12, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104432
- GRCh38:
- Chr16:2054431
| TSC2 | E109*, R9S, E169*, E188*, E121*, E139*, E158* | Tuberous sclerosis 2 | Pathogenic (Sep 26, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104435
- GRCh38:
- Chr16:2054434
| TSC2 | E159*, E170*, E110*, E122* | Tuberous sclerosis 2 | Pathogenic (Dec 15, 2017) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104438
- GRCh38:
- Chr16:2054437
| TSC2 | L160V, L171V, L111V, L123V | not provided | Likely pathogenic (May 10, 2017) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104442
- GRCh38:
- Chr16:2054441
| TSC2 | | Cortical tubers, Focal cortical dysplasia, Tuberous sclerosis 2
| Pathogenic (Jul 12, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2104442
- GRCh38:
- Chr16:2054441
| TSC2 | | Tuberous sclerosis syndrome | Pathogenic (Jun 15, 2018) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104446
- GRCh38:
- Chr16:2054445
| TSC2 | | Tuberous sclerosis 2 | Pathogenic (Aug 27, 2021) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2104446
- GRCh38:
- Chr16:2054445
| TSC2 | | not provided | Pathogenic (Feb 1, 2017) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2105402
- GRCh38:
- Chr16:2055401
| TSC2 | | not provided | Pathogenic (Aug 10, 2016) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2105402
- GRCh38:
- Chr16:2055401
| TSC2 | | Tuberous sclerosis 2 | Likely pathogenic (Jan 4, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2105408-2105409
- GRCh38:
- Chr16:2055407-2055408
| TSC2 | F114fs, F163fs, F126fs, F174fs | not provided, Tuberous sclerosis 2 | Pathogenic (Nov 7, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2105417
- GRCh38:
- Chr16:2055416
| TSC2 | Q166*, Q177*, Q117*, Q129* | not provided, Tuberous sclerosis 2 | Pathogenic (Oct 23, 2022) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2105420-2105427
- GRCh38:
- Chr16:2055419-2055426
| TSC2 | W118fs, W178fs, W130fs, W167fs | Tuberous sclerosis 2 | Pathogenic (Jul 23, 2022) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2105421
- GRCh38:
- Chr16:2055420
| TSC2 | W167*, W178*, W118*, W130* | Tuberous sclerosis 2, not provided | Pathogenic (Nov 7, 2021) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- Chr16:2105422
- GRCh38:
- Chr16:2055421
| TSC2 | W130*, W178*, W118*, W167* | Lymphangiomyomatosis | Pathogenic (Nov 14, 2018) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2105427
- GRCh38:
- Chr16:2055426
| TSC2 | D120fs, D169fs, D132fs, D180fs | not provided | Pathogenic (Jul 3, 2018) | criteria provided, single submitter |
| - GRCh37:
- Chr16:2105434-2105435
- GRCh38:
- Chr16:2055433-2055434
| TSC2 | L135fs, L123fs, L172fs, L183fs | Tuberous sclerosis 2 | Pathogenic (Feb 22, 2022) | criteria provided, single submitter |